Search
Now showing items 1-2 of 2
Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
(ELSEVIER IRELAND LTD, 2017-05-01)
Malignant mesothelioma remains an incurable cancer. We demonstrated that mesotheliomas expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but lacked ErbB3. At least one ErbB family member was expressed in 88% of tumors. ...
Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy.
(AMER ASSOC CANCER RESEARCH, 2023-09-11)
UNLABELLED: Surgical cytoreduction for patients with malignant pleural mesothelioma (MPM) is used for selected patients as a part of multi-modality management strategy. Our group has previously described the clinical use ...